Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967298 | 0.87 | CCR5 (0.87) | CCR5KCNH2 | |
| SCHEMBL1133688 | 0.86 | CCR5 (0.78) | CCR5KCNH2 | |
| SCHEMBL1133686 | 0.85 | CCR5 (0.76) | CCR5KCNH2 | |
| SCHEMBL4123857 | 0.85 | CCR5 (1.00) | CCR5 | |
| SCHEMBL4211841 | 0.83 | CCR5 (0.81) | CCR5KCNH2 | |
| SCHEMBL3959068 | 0.83 | CCR5 (0.81) | CCR5 | |
| SCHEMBL3633426 | 0.82 | CCR5 (0.89) | CCR5KCNH2 | |
| SCHEMBL4487387 | 0.82 | CCR5 (0.89) | CCR5KCNH2 | |
| SCHEMBL1133936 | 0.82 | CCR5 (0.71) | CCR5KCNH2 | |
| SCHEMBL1133361 | 0.82 | CCR5 (0.71) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285807-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-02-23 | — | — | EP | claimed |
| WO-2009135788-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-12 | — | — | WO | claimed |
| US-20090281133-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-11-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281133-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | CCR5 1/4885KCNH2 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.